... elderly as ≥65 years. This study aims to determine outcomes of induction immunosuppression in patients aged ≥75 years. Methods: A cohort of patients aged ≥75 years with a diagnosis of AAV between 2006 and 2018 was constructed from 2 centres. Follow-up was to 2 years or death. Analysis included...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Nephrotic syndrome Minimal change disease Immunosuppression Corticosteroid Nephrotic syndrome manifests...

... (interquartile range [IQR] 15–34) glomeruli with 96% showing moderate to severe interstitial fibrosis. Overall, 96% of patients received immunosuppressive drug therapy and 16% received plasmapheresis. Treatment response was achieved in all but 1 patient. The median (IQR) eGFR at entry was 14.5 (9–19) mL/min/1.73...

...D. Geetha; S.M. Levine; R.L. Manno; A. Valsamakis; S. Ghazarian; P. Seo Background: BK virus (BKV) is an important cause of renal dysfunction in kidney transplant (KTX) recipients. Immunosuppression intensity is a major risk factor for BKV replication in these patients. The prevalence of BKV...

... CD4 + , CD25 - cells into functionally immunosuppressive CD4 + , CD25 + cells. More importantly, the CD4 + , CD25 high Foxp3 + Treg cells generated by thymoglobulin were shown to suppress a direct alloimmune response in a mixed lymphocyte reaction, but did not suppress the memory response...

... the increased clinical risk and the optimal dialysis modality in renal allograft loss, explore new approaches to immunosuppression and transfusion management, and examine the risks and benefits of allograft nephrectomy and timing thereof. While there are no randomized clinical trials in this field, rapidly...

... different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000;69:436–439. 11. Kumar SS, Ventura AK, VanderWerf B: Influenza vaccination in renal transplant recipients. JAMA 1978;239:840–842. 12. Huang KL, Armstrong JA, Ho M: Antibody response...

.... Glomerulonephritis Immunosuppression Animal models Apoptosis National Institutes of Health (NIH) 10.13039/100000002 Spontaneous recovery from autoimmune diseases has been reported in both human patients and animal models [ 1,2,3,4 ]. By mimicking those natural recovery mechanisms, we may...

... recipients to determine the sizes of the Treg populations and the effects of treatment regimens thereof. Methods: All patients (19 with good graft function and 20 with chronic allograft nephropathy) received induction therapy (basiliximab) and were on triple immunosuppressive regimens with calcineurin...

... was positive in 34 (24%), while plasma PCR turned positive in 22 cases (15%). No patients developed viremia with <6.8 log copies in the urine. Viremia resolved within 3 months or less in 20 of 22 patients after reduction of immunosuppression. Surveillance biopsies at 2 and 6 months revealed no BK...

...Leandro P. Araujo; Renata R. Truzzi; Gloria E. Mendes; Marcus A.M. Luz; Emmanuel A. Burdmann; Sonia M. Oliani Background: Tacrolimus (FK) is currently widely used in transplant immunosuppression and the treatment of autoimmune diseases. However, FK induces nephrotoxicity which is characterized...

...Thomas Rath; Vilma Oliveira-Frick Background: Immunosuppressive therapy is essential for patients after renal transplantation, but it may have mutagenic side effects. The frequency of micronuclei (MN) assessed by the cytokinesis block assay is well established in the diagnosis of DNA damage...

... transplant patients, with an incidence rate of 8.3 (95% CI 7.8–8.9) cases per 1,000 patient-years. Mean time to diagnosis of TRAS was 0.83 ± 0.81 years after transplant. Factors associated with TRAS were older recipient and donor age, extended criteria donors, induction immunosuppression, delayed graft...

... that after renal IRI, bone marrow-derived cells (BMDC) can differentiate to interstitial myofibroblasts. Here we hypothesized that the immunosuppressant ciclosporin A (CsA), known for its profibrotic side effect, promotes myofibroblast differentiation of BMDC in the postischemic kidney. Methods: Using...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Glomerulonephritis Immunosuppression Corticosteroids Alkylating agents Minimal change disease Focal segmental glomerulosclerosis Membranous nephropathy Mesangiocapillary nephritis IgA...

... the second group died of peritonitis due to intestinal lesions. In these 2 patients, immunosuppressive therapy had either been increased or reintroduced after a partial regression of KS. In all other patients, therapy was promptly reduced or withdrawn. In 1 patient local radiation therapy plus intralesional...

... Proteinuria Minimal-change nephropathy Focal glomerulosclerosis Immunosuppression Am J Nephro! I990;10(supp! 1):105 109 © 1990 S. Karger AG, Base! 0250-8095/90/0107-0105S2.75/0 Ciclosporin in Minimal-Change Glomerulopathy and in Focal Segmental Glomerular Sclerosis Claudio Ponticelli, Emilio Rivolta...

...); 34 received conventional immunosuppression. Eighty-seven RT patients were found to be HCV-positive (2.5%) when assessed by ELISA-2 tests; RIBA-2 was positive in 61 cases and ‘indeterminate’ in 26. Most of the HCV-positive patients had antibodies against C22-3 (94%), whereas antibodies against...

... recommend the use of high doses of ACV for the first 3 months after transplantation in high-risk renal transplant patients, i.e. D+/R-. Renal transplantation Acyclovir Cytomegalovirus Anti-cytomegalovirus Immunoglobulins Rejection Immunosuppression NephrologyT M American% Journalof Clinical...

... support the assumption that excess blood levels of PTH may have an immunosuppressive effect. Parathyroid hormone Immunosuppression 20 10 1987 9 07 1988 28 10 2008 © 1989 S. Karger AG, Basel 1989 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...